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Abstract
Background: Since the mid-1980's there has been a worldwide resurgence of severe disease from
group A streptococcus (GAS), with clonal clusters implicated in Europe and the United States.
However GAS associated sepsis and rheumatic fever have always remained at high levels in many
less developed countries. In this context we aimed to study GAS necrotising fasciitis (NF) in a
region where there are high background rates of GAS carriage and disease.
Methods: We describe the epidemiology, clinical and laboratory features of 14 consecutive cases
of GAS NF treated over a seven year period from tropical northern Australia.
Results: Incidence rates of GAS NF in the Aboriginal population were up to five times those
previously published from other countries. Clinical features were similar to those described
elsewhere, with 7/14 (50%) bacteremic and 9/14 (64%) having associated streptococcal toxic shock
syndrome. 11/14 (79%) had underlying chronic illnesses, including all four fatalities (29% mortality
overall). Important laboratory differences from other series were that leukocytosis was absent in
9/14 (64%) but all had substantial lymphopenia. Sequence typing of the 14 NF-associated GAS
isolates showed no clonality, with only one emm type 1 and two emm type 3 strains.
Conclusions: While NF clusters can occur from a single emergent GAS clone, this was not
evident in our tropical region, where high rates of NF parallel high overall rates of GAS infection
from a wide diversity of strains. The specific virulence factors of GAS strains which do cause NF
and the basis of the inadequate host response in those patients who develop NF on infection with
these GAS require further elucidation.
Background
Necrotising fasciitis (NF) is an aggressive and rapidly
destructive soft tissue infection resulting in high mortality
and significant long term morbidity. Two groups of infec-
tious agents have been described – Type I which are pol-
ymicrobial, involving anaerobic bacteria and streptococci
other than serogroup A, and Type II from Streptococcus pyo-
genes (Group A streptococci, GAS) alone, or in association
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with Staphylococcus aureus or Staphylococcus epidermidis [1].
The latter was originally described by Meleney in 1924 as
'haemolytic streptococcal gangrene' [2] and has since
been considered a rare entity.
Since the mid-1980's a worldwide increase in infections
due to GAS has been noted. In affluent populations where
GAS disease is uncommon aside from pharyngitis in
childhood, increasing numbers of necrotising fasciitis and
streptococcal toxic shock syndrome (STSS) have been
seen, as well as an upsurge of acute rheumatic fever appar-
ently restricted to parts of the United States [3-6]. This has
been attributed in some locations to dissemination of a
virulent M1 serotype GAS clone[7]. In developing nations
the pattern of GAS disease is different, with continuing
high rates of streptococcal pyoderma and post-streptococ-
cal disease[8].
Recent case series of GAS NF have been published from
Norway[4] and Ontario, Canada[5,6]. The Northern Ter-
ritory (NT) of Australia consists of a combination of afflu-
ent, urban residents, as well as residents in remote
communities, who are predominantly indigenous Aborig-
inals with high levels of poverty and overcrowding. As in
developing nations, these remote communities have very
high rates of GAS disease in the form of streptococcal pyo-
derma, rheumatic fever and post-streptococcal glomeru-
lonephritis[9]. We examine the epidemiology, clinical
features and streptococcal sequence typing of a series of
cases of GAS NF from the tropical top end of the NT and
compare the results with the literature.
Methods
The Royal Darwin Hospital services 135,000 inhabitants
of the NT, with around 100,000 located in the city of Dar-
win. Indigenous Aboriginal Australians account for 24%
of the population[10]. Cases of possible GAS NF treated at
Royal Darwin Hospital were prospectively identified. Case
definition for inclusion in the analysis required GAS to be
cultured from sterile sites, notably operative tissue speci-
mens +/- blood cultures. NF was defined by necrosis of
subcutaneous tissue, specifically fascial oedema and
necrosis detected either macroscopically at surgery, or
microscopically on histopathology.
Fourteen cases fulfilling the case definition were identified
between May 1994 and April 2001. A chart review was
conducted to identify epidemiological characteristics,
clinical features, laboratory results, treatment and out-
comes. Age, gender, ethnicity, urban or rural residence
and any concurrent medical conditions were docu-
mented. The dates of presentation, presumptive diagnosis
of NF and of surgery were documented. Symptoms, signs,
hemodynamic status and temperature were documented
for these dates, as was the presence of STSS as defined by
the Working Group on Severe Streptococcal Infec-
tions[11]. Antibiotic treatment, surgery, and any adjuvant
therapies were documented. Baseline hematological and
biochemical parameters were recorded for the date of
presentation, and blood and tissue culture results were
documented. Duration of Intensive Care Unit (ICU)
admission, and type of ICU support required were
recorded.
Incidence rates of GAS NF for this region of the NT were
calculated using regional population numbers from cen-
sus data. There was possibly an increase in case ascertain-
ment after 1998 and incidence rates were also calculated
by year.
Procedures for emm sequence typing and analysis of emm-
specific PCR products were carried out as previously
described[12]. DNA sequences were subject to homology
searches against all emm sequences deposited in GenBank
and in the Centers for Disease Control (CDC) Streptococ-
cus pyogenes emm sequence database[13].
Approval for the study was obtained from the Health
Research Ethics Committee of Royal Darwin Hospital and
the Menzies School of Health Research.
Results
Table 1 summarizes the details for each patient.
From 1994 to 2001, 14 cases of confirmed GAS NF were
treated at Royal Darwin Hospital. The number of cases per
year ranged from zero in 1995 and 1998 to five in 2001.
This gives a maximum yearly incidence of 3.8 cases per
100,000. Half of the cases occurred in Aboriginal patients,
with an incidence of 5.8 per 100,000 for Aboriginals in
the 2001 cluster of cases. Eight cases occurred in women
(57%), five of whom were Aboriginal. Ages ranged from
27–61 years in males (mean 41.5 yrs) and 27–59 years in
females (mean 41.5 yrs). Eleven cases were community
acquired and three nosocomial. All seven Aboriginal
patients had multiple concurrent medical conditions,
whereas three of the seven non-Aboriginals had no addi-
tional pathology.
Patients presented most consistently with pain in the
affected area. The other common complaints were swell-
ing, and systemic symptoms of fever and rigors. Signs on
presentation were typically induration and tense swelling
of the area. Only four of the fourteen cases (29%) were
noted to have extensive skin erythema, but nine (64%)
had local pre-existing wounds or ulceration. Ten patients
had only limb involvement, two had chest wall involve-
ment, one had extension from right leg to the abdominal
wall and one had extension from the left buttock to peri-
neum/labia. STSS occurred in nine patients. Ten patientsBMC Infectious Diseases 2004, 4:60 http://www.biomedcentral.com/1471-2334/4/60
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Table 1: Demographic, clinical and laboratory details of 14 patients with GAS necrotising fasciitis
No Age/
Gender/
Aboriginal/
Year
Co-
morbidities
Prior 
lesions
Systolic BP 
at 
presenttion 
(mmHg)
Creatinine 
(µmol/L) 
(NR 50–
100)
Blood 
culture
emmSTa STSSb
1 45/F/Y/2001 Alcohol 
excess
Right knee 
abrasion
85 810 Neg new emmST Y
2 50/F/Y/1994 Rheumatoid 
arthritis
Nil 100 352 Pos emm56 N
3 47/F/Y/2000 Hemodialysis, 
Hypertension
Nil 85 739 Pos emmST3757 Y
4 38/F/Y/2001 Type 2 
diabetes, 
Hemodialysis, 
Cryptococcal 
pneumonitis
Buttock ulcer 60 408 Pos no sequence Y
5 61/M/N/2001 Rheumatoid 
arthritis, 
Corticosteroi
d therapy, 
Splenectomy
Vasculitic leg 
ulcer
70 249 Pos emm3.2 Y
6 60/M/N/2001 Rheumatoid 
arthritis, 
Methotrexate 
therapy, 
Pulmonary 
fibrosis
Leg ulcer 90 237 Neg emm70 Y
7 27/M/N/1996 Alcohol 
excess
Nil 70 172 Neg emm58 Y
8 34/F/Y/1996 SLE, Anti-
Phospholipid 
syndrome, 
Corticosteroi
ds, Renal 
impairment
Left thigh skin 
sore
100 329 Pos emm69 N
9 44/M/Y/2000 Type 2 
diabetes, 
Alcohol 
excess, Renal 
impairment
Wound from 
catfish barb
90 271 Neg emm49.3 Y
10 27/F/N/1999 Nil Nil 90 77 Neg emm104 N
11 32/F/N/1999 Nil Buttock 
excoriation 
post-cycling
100 177 Neg emm1N
12 59/F/N/1999 Nil Nil 90 118 Neg emm22 Y
13 50/M/Y/1997 Alcohol 
excess, 
Cirrhosis
Leg ulceration 100 112 Pos emm4N
14 61/M/N/2001 Alcohol 
excess, 
Hypertension, 
Gout
Ulcerated 
gouty tophus
90 659 Pos emm3Y
No WCC/
Lymphc 
(×109/L)
Albumin (g/
L) (NR 35–
45)
Infection 
site
Time to 
surgery 
after 
presentatio
n
Operation 
performed
Antibiotic 
therapy
Myo-
necrosis
Died
1 5.7/0.2 21 Right leg 4 days Debridement, 
Fasciotomy
Meropenem, 
Clindamycin
Yes Yes
2 5.2/0.5 22 Right arm 6 days Fasciotomy Penicillin Yes Yes
3 9.6/0.3 33 Right breast/
Chest wall
5 days Debridement Penicillin No Yes
4 9.3/0.4 34 Left leg/
Abdominal 
wall
2 days Debridement Penicillin, 
Clindamycin
No YesBMC Infectious Diseases 2004, 4:60 http://www.biomedcentral.com/1471-2334/4/60
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required inotropic support, six had a documented coagu-
lopathy and eleven had renal impairment. Thirteen
patients (93%) required ICU stay of 1–24 days. Eleven
patients were ventilated, and six received renal replace-
ment therapy.
Total white cell count (WCC) was found to be raised (>11
× 109/L) in only 5/14 (36%) patients, although lym-
phocyte count was globally reduced, being <1.0 × 109/L in
all patients, and <0.5#215;109/l in nine cases (64%).
Renal function was frequently impaired, with 11/14
(79%) patients having raised urea (mean 17.7 mmol/L,
NR 3.0–8.0 mmol/L) and 12/14 (86%) having raised cre-
atinine (mean 301 µmol/L, NR 50–100 µmol/L). All
patients were hypoalbuminemic with 11 having albumin
<30 g/L (mean 24.5, range 11–34, NR 35–45 g/L) Plasma
creatine kinase (CK) ranged from 25 U/L to 2526 U/L (NR
<220 U/L), being elevated in 5/9 (56%) patients meas-
ured. C-Reactive Protein (CRP) was substantially raised in
all 11 where measured, being between 108–522 mg/L
(NR<10). Blood cultures were positive for GAS in seven
cases (50%). GAS was isolated from all operative tissue
specimens, with four also positive for S. aureus.
One GAS isolate could not be sequenced. GAS from the
other 13 patients showed a large diversity of emm
sequence types, with no clonality. Where blood and tissue
GAS were both recovered from an individual, the emm
sequence types were the same. One patient's GAS isolate
was a previously uncharacterized emm sequence type and
there was only one case with emm sequence type 1 GAS
isolated. The two emm 3 isolates were from the 2001 clus-
ter of five cases. However they were very divergent on ran-
dom amplified polymorphic DNA analysis (data not
shown), one being emm sequence type 3.2, and the other
three isolates in this cluster were all different emm types.
All patients underwent surgery 0–7 days after presenta-
tion. Debridement alone was conducted in nine patients,
and combined with fasciotomy in one case. Fasciotomy
alone was done in one case. Three patients underwent
limb amputation. At surgery it was established that three
patients (21%) had concurrent myonecrosis. Antibiotic
therapy was instituted with a beta lactam in all patients
(benzylpenicillin in nine, meropenem in three, cephazo-
lin in one and flucloxacillin in one). Clindamycin was
also given in eleven patients. Adjuvant hyperbaric oxygen
therapy was given in four cases, and intravenous immu-
noglobulin (IVIG) in one.
Four patients (29%) died, all being Aboriginal females
with co-morbidities. Two of the four patients with truncal
infection died in comparison to only two of the ten with
only peripheral involvement. The mean time to surgery
from presentation was 4.25 days in patients who died and
3.7 days in survivors (not significant). Blood cultures were
5 36.7/0.7 23 Left leg 1 day Above knee 
amputation
Meropenem, 
Tobramycin, 
Clindamycin
No No
6 23.7/0.5 29 Right leg 0 days Below knee 
amputation
Cefazolin, 
Clindamycin
No No
7 5.2/0.1 25 Right leg 5 days Debridement Penicillin, 
Clindamycin
No No
8 7.0/0.3 33 Left leg/
Abdominal 
wall
7 days Debridement Penicillin, 
Clindamycin
Yes No
9 22.8/0.8 11 Right foot 2 days Above knee 
amputation
Flucloxacillin, 
Metronidazol
e, Gentamicin
Yes No
10 23.3/1.0 29 Left shoulder/
Chest wall
6 days Debridement Meropenem, 
Clindamycin
No No
11 21.8/0.5 17 Right leg/
Buttock/
Perineum
2 days Debridement Penicillin, 
Clindamycin
No No
12 4.8/0.4 18 Left leg/
Abdominal 
wall
2 days Debridement Penicillin, 
Clindamycin
No No
13 10.5/0.7 21 Left leg 5 days Debridement Penicillin, 
Clindamycin
No No
14 4.0/0.2 28 Right leg 4 days Above knee 
amputation
Penicillin, 
Clindamycin
No No
a Emm sequence type (see methods for details)
b Streptococcal toxic shock syndrome (see methods for details)
c WCC-total blood white cell count (normal range <11.0 × 109/L) Lymph-blood lymphocyte count
Table 1: Demographic, clinical and laboratory details of 14 patients with GAS necrotising fasciitis (Continued)BMC Infectious Diseases 2004, 4:60 http://www.biomedcentral.com/1471-2334/4/60
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positive in 3/4 fatalities with STSS in 3/4. All four were in
ICU for 1–5 days until death, with all requiring inotropes
and mechanical ventilation, two given renal replacement
therapy and one IVIG. Two received clindamycin in addi-
tion to beta-lactam antibiotic therapy. Surgery in the fatal
cases consisted of debridement and/or fasciotomy, with
no amputation.
Discussion
Demographics
We describe a series of 14 cases of GAS necrotising fasciitis
in a region with a high background incidence of GAS dis-
ease[9]. Our incidence of NF in 2001 of 3.8/100,000 and
5.8/100,000 in the Aboriginal population is higher than
previously published rates which range from 0.4/100,000
in Canada[5] to 2/100,000/yr in Norway [4]. However the
population denominators in the Canadian and Norwe-
gian studies are far greater than in our study. Nevertheless,
previous data from our region showed that rates of GAS
bacteremia in the Aboriginal population were five times
those in the Caucasian population[9]. Therefore NF in our
population parallels an overall greater rate of GAS infec-
tion, most notably in the Indigenous population where
conditions reflect those of developing countries[8].
The mean age of our patients (41.5 years) is lower than
other reports showing an average age of 56–58 years, with
notable increases in incidence with increasing age[4-6].
Unlike all other series which had a male predominance,
57% of our cases were female, with 71% females amongst
the Aboriginal cases. The age and sex pattern seen in our
series reflects the high rates of chronic diseases in the
Indigenous population, with mortality from all causes
being higher in all age cohorts, but especially so in
females[14,15]. 79% of our patients had concurrent
chronic disease, compared with 46–71% in previous
series[4-6,16]. In this series 64% had pre-existing wounds,
consistent with reported rates of 47–66%[4-6,16]. None
of our patients had preceding varicella infection.
Laboratory results
Two studies have looked at the value of early blood test
results in predicting NF as opposed to non-NF soft tissue
infection. One found that CK >600 U/L achieved PPV of
58% for NF[17]. However only 1/9 cases in this series had
CK >600 U/L. CRP of >16 mg/L was also thought to be
indicative of NF[16]. CRP was over 100 in all those meas-
ured in our series. Raised WCC has also been suggested as
useful in a predictive model of early NF[18], with rates of
66–73% in other series[4-6]. However, only 36% of our
patients had a raised WCC. We found lymphopenia to be
a more consistent factor, with 100% of patients having a
lymphocyte count of <1.0 × 109/L, 64% of those being
<0.5 × 109/L. Low albumin was also universal.
Clinical features
STSS occurred in 64% of our cases in comparison to 40–
46% in other series[4-6]. 71% of our patients were hypo-
tensive at presentation, with 86% having renal impair-
ment in comparison to 35–61% in other series. Similarly
to the other series, 93% of our patients were admitted to
the ICU but more of our patients required mechanical
ventilation (79%) and inotropic support (71%). Positive
blood cultures are not a prerequisite for GAS NF, as stated
by Meleney in the initial descriptions[2], and reinforced
in subsequent studies showing bacteremic rates of 38–
60%[4-6,16], consistent with 50% in this study.
Case-fatality rates for NF previously reached 50%, with
mortality of 80–100% in GAS myositis[3]. Recent series
report lower case-fatality rates of 20–34%[4-6], with our
mortality being 28%. As in previous studies, deaths were
more common in those with underlying illness, truncal
infection, bacteremia, STSS, myonecrosis and delay in
diagnosis and appropriate therapy.
Therapy
Immediate, extensive surgical debridement of all necrotic
tissue is considered essential for optimal treatment of NF,
with one early observational study showing a mortality of
0% with aggressive early surgery in comparison to 50% in
historical controls[19,20]. Surgery was conducted on the
day of presumptive diagnosis of NF in all our patients, but
none of the four fatal cases underwent amputation and
one with upper limb involvement had only a fasciotomy
performed.
Combination therapy with benzylpenicillin and clin-
damycin is now recommended treatment for proven GAS
NF and STSS[21-23]. Experimental data suggest that pen-
icillin is not as bactericidal when there are large numbers
of GAS organisms present[24], with decreased expression
of penicillin binding proteins when large inocula reach a
stationary growth phase[25]. The potential benefits of
clindamycin have been supported by a murine model of
streptococcal myositis[26]. Clindamycin is a protein syn-
thesis inhibitor, potentially also suppressing bacterial
toxin and M protein production[25]. Furthermore, clin-
damycin may modulate the host immune response, by
reducing lipopolysaccharide-induced monocyte produc-
tion of TNFα[27]. A combination of β-lactam antibiotic
and clindamycin has been shown to be superior to β-
lactams alone in a retrospective review of invasive GAS
infection in 56 children[28]. A recent retrospective review
of notified invasive GAS infections in Florida, USA
showed the use of clindamycin to be associated with
lower mortality in NF cases, but not in other invasive GAS
infections[29]. However there have been no randomised
clinical trials.BMC Infectious Diseases 2004, 4:60 http://www.biomedcentral.com/1471-2334/4/60
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Hyperbaric oxygen (HBO) therapy has been advocated as
adjuvant therapy for both microbiological types of NF.
Although there are no randomised trials, NF is an
approved Undersea and Hyperbaric Medical Society indi-
cation for HBO therapy[30]. It is suggested that increased
tissue oxygen partial pressures increases bacterial killing
by increased respiratory burst and increased formation of
oxygen free radicals. HBO is postulated to facilitate
wound healing by supporting fibroblast proliferation and
angiogenesis[30,31]. In a murine model of GAS myositis,
the combination of penicillin and HBO therapy exerted at
least additive effects in decreasing bacterial counts in vivo
and increasing survival[32]. An observational study of 29
patients with NF showed significantly lower mortality,
and need for fewer debridements in those receiving
adjunctive HBO, despite the HBO group being more seri-
ously ill[33]. Patients with non-clostridial fasciitis
appeared to have greater benefit. However more recently
a retrospective evaluation of 37 patients treated for NF
showed higher mortality with greater need for debride-
ment in those receiving HBO[34].
The clinical picture of STSS has been attributed to super-
antigens produced by GAS, including pyrogenic exotox-
ins, streptococcal superantigen SSA and a mitogenic
exotoxin[35]. This is supported by selective depletion of
Vβ-bearing T cells in patients with STSS[36]. However
GAS isolates from both severe and uncomplicated disease
can produce large amounts of toxins. Furthermore, in
comparison to patients with uncomplicated infection the
sera of patients with severe GAS disease had low antibody
levels against erythrogenic toxins[37], suggesting an
important role for host humoral immunity. IVIG has
therefore been proposed as therapy to increase neutraliz-
ing antibody levels in patients with severe GAS disease. A
study of 12 patients, 11 with STSS and one with GAS NF,
showed increased capacity of plasma to neutralize super-
antigenic activity following IVIG[38]. Post-IVIG plasma
from each patient completely blocked cytokine produc-
tion elicited by their respective GAS culture supernatants
or by purified streptococcal pyrogenic exotoxins. GAS
superantigens and cytokines suggestive of superantigen
response have been isolated from tissue samples in
patients with GAS NF[39]. More severe clinical disease
correlated with significantly higher bacterial load in
biopsy samples, and bacterial load in turn correlated with
expression of superantigenic toxins. This supports a role
for IVIG in GAS NF, with or without STSS. Adjunctive IVIG
therapy in STSS was evaluated in a multicenter, rand-
omized, double-blind, placebo-controlled trial[40].
Although prematurely terminated due to slow patient
recruitment, there was a non-significant 3.6 fold higher
mortality rate in the placebo group and a significant
decrease in sepsis-related organ failure assessments on
days two and three in the IVIG group. There are case
reports and two case series of four and seven patients
describing clinical improvements of patients with STSS
following IVIG[41-43]. In a series of 20 cases of GAS NF
and myonecrosis, 16 were treated with IVIG[6]. Although
the case fatality rate was not significantly lower in those
receiving IVIG, the overall survival rates of 80% in patients
with NF and 63% in patients with myonecrosis were
much higher than previously reported[6].
In summary, there is in vitro and in vivo experimental
data to suggest a benefit for clindamycin, HBO therapy
and IVIG in GAS NF and myositis. This is supported by
limited case series but not by randomized controlled tri-
als. The primary role of early, aggressive surgery in GAS NF
remains probably the most critical factor in minimizing
mortality. Clindamycin is recommended for GAS NF but
whether clindamycin alone is as effective as penicillin
plus clindamycin remains unclear. Benefit from HBO
remains unproven, while there is emerging evidence for
the use of IVIG, especially if STSS is present.
Molecular epidemiology
Following a reported resurgence in invasive GAS infec-
tions in the 1980's, epidemiological studies proposed that
dissemination of a new, more virulent strain of M1 sero-
type GAS was the cause for a large proportion of these
infections[7]. In reports from the United States, Europe
and New Zealand the proportion of this strain appeared
to increase, both in those with uncomplicated pharyngitis
and in invasive GAS infections[37,44-47]. The M1 sero-
type has also been reported to have a stronger association
with STSS[48]. In contrast to these findings, other groups
have noted a significant diversity amongst the organisms
causing severe streptococcal infections, as well as signifi-
cant clinical variation amongst patients infected with
identical organism clones, suggesting that the severe infec-
tions are not related to one specific virulent clone[49-51].
Our findings are consistent with the latter, with GAS
sequence typing showing all NF isolates to be different
and only 1/13 to be emm type 1. This reflects previous
findings of enormous diversity amongst organisms caus-
ing GAS bacteremia in our region, with no evidence of a
dominant clone[9]. As well as finding no correlation
between NF and specific M types, a recent Dutch study
also found that no specific toxin genes or genes encoding
matrix binding proteins were associated with NF[48].
Conclusions
In conclusion we have described a case series of necrotis-
ing fasciitis due to GAS for a unique mixed population of
patients living in both affluent and disadvantaged society.
Our overall incidence rates of GAS NF are higher than pre-
viously reported, with rates in the Aboriginal population
up to five times those previously published. The majority
of those with NF had underlying chronic illnesses andBMC Infectious Diseases 2004, 4:60 http://www.biomedcentral.com/1471-2334/4/60
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mortality was also higher in this group. Important labora-
tory findings were that leukocytosis was absent in more
than half of cases but all had substantial lymphopenia.
Emm sequencing typing of GAS isolates showed none to
be the same and only 1/13 to be emm1. GAS NF in our
region is not clonal but occurs from a wide diversity of
GAS strains that reflect the very high background rate of
both uncomplicated GAS infection and invasive disease.
While NF case clusters can occur from a single emergent
GAS clone, this is not evident in our tropical region. The
specific virulence factors of the GAS which do cause NF
and the basis of the inadequate host response in those
patients who develop NF on infection with these GAS
require further elucidation.
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